Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Listen to downloadable audio from a series of live Webinars by Ira M. Jacobson, MD, and Paul Y. Kwo, MD, in which the optimal management of patients with HCV who have achieved SVR is discussed and audience questions are answered.
Format: Audio (.mp3)
File Size: 10.01 MB
Released: February 14, 2018

Listen to downloadable audio from a series of live Webinars by Ira M. Jacobson, MD, and Paul Y. Kwo, MD, in which the optimal management of patients with HCV who have achieved SVR is discussed and audience questions are answered. (~45 minutes)

Ira M. Jacobson, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, and Trek; fees for non-CME/CE services from Gilead Sciences, Intercept, and Merck; and funds for research support from Gilead Sciences and Merck.

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck and funds for research support from AbbVie and Gilead Sciences.

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Educational grant provided by:
AbbVie
Gilead Sciences
Merck & Co., Inc.

Related Content

Cohort study of HCV reinfection rates after successful DAA treatment in persons who inject drugs, as reported by Clinical Care Options (CCO) at AASLD 2019

Released: November 20, 2019

Data on HCC risk with spontaneous and NA-induced HBsAg loss as reported from AASLD 2019 by Clinical Care Options (CCO)

Released: November 19, 2019

Data from AASLD 2019 showing the benefits of regular follow-up on HCC mortality in chronic hepatitis B as reported by Clinical Care Options (CCO)

Released: November 19, 2019

Scoring method for identifying patients with low risk of HCC after SVR with HCV therapy as reported by Clinical Care Options from AASLD 2019.

Released: November 18, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?